NLRP3 and early-onset autosomal dominant Alzheimer disease: The NLRP3 inflammasome has been reported to participate in the development of diverse inflammatory diseases, including type 2 diabetes, Alzheimer’s disease, and gout6–11, suggesting that NLRP3 might be a potential target for the treatment of inflammatory diseases.